Published in Haematologica on February 23, 2010
Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer (2012) 2.35
The hematopoietic stem cell niche--home for friend and foe? Cytometry B Clin Cytom (2012) 1.70
The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression. Br J Cancer (2012) 1.18
The immunomodulatory properties of mesenchymal stem cells. Semin Immunopathol (2011) 1.16
Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci U S A (2011) 1.10
The bone marrow microenvironment and leukemia: biology and therapeutic targeting. Expert Rev Hematol (2011) 1.08
Mesenchymal stromal cells: a key player in 'innate tolerance'? Immunology (2012) 1.07
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia (2011) 1.06
Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia (2011) 1.06
Mesenchymal stem cells: angels or demons? J Biomed Biotechnol (2011) 1.04
Aging of the microenvironment influences clonality in hematopoiesis. PLoS One (2012) 1.00
Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia. PLoS One (2011) 1.00
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem Pharmacol (2010) 0.96
Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer. Cell Cycle (2015) 0.88
Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. Oncotarget (2015) 0.88
Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget (2016) 0.85
[Tumor stem cell research - basis and challenge for diagnosis and therapy]. Wien Klin Wochenschr (2010) 0.80
CRIF1 interacting with CDK2 regulates bone marrow microenvironment-induced G0/G1 arrest of leukemia cells. PLoS One (2014) 0.80
Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors. Oncoscience (2014) 0.79
Tyrosine kinase inhibitors and interferon. Mediterr J Hematol Infect Dis (2014) 0.79
Cancer associated fibroblasts in hematological malignancies. Oncotarget (2015) 0.79
Engineered Mesenchymal Stem Cells as an Anti-Cancer Trojan Horse. Stem Cells Dev (2016) 0.78
Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation. Oncotarget (2016) 0.76
Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events. BMC Cancer (2011) 0.76
Chronic myelogenous leukaemia exosomes modulate bone marrow microenvironment through activation of epidermal growth factor receptor. J Cell Mol Med (2016) 0.76
β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia (2015) 0.75
Granulocyte colony-stimulating factor inhibits CXCR4/SDF-1α signaling and overcomes stromal-mediated drug resistance in the HL-60 cell line. Exp Ther Med (2016) 0.75
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell (2004) 12.67
Stromal fibroblasts in cancer initiation and progression. Nature (2004) 11.69
TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science (2004) 10.23
Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res (1999) 8.63
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood (2002) 6.64
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood (2006) 4.41
Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood (2004) 4.03
Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res (2000) 3.95
Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest (2003) 3.52
Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res (2001) 3.48
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat Med (1998) 3.20
Stromal cells can contribute oncogenic signals. Semin Cancer Biol (2001) 2.80
Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood (2007) 2.68
Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood (1998) 2.66
Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-beta. Science (1990) 2.22
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest (2007) 2.05
Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia (2006) 2.04
Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation (2007) 1.83
Role of mitochondria as the gardens of cell death. Cancer Chemother Pharmacol (2005) 1.56
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther (2008) 1.49
Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia (2005) 1.49
Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells. Cancer Res (2006) 1.28
Effects of the chemokine stromal cell-derived factor-1 on the migration and localization of precursor-B acute lymphoblastic leukemia cells within bone marrow stromal layers. Leukemia (2000) 1.06
p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res (2005) 1.02
A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia (2009) 0.93
Long-term culture of infant leukemia cells: dependence upon stromal cells from the bone marrow and bilineage differentiation. Leuk Res (1986) 0.89
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol (2009) 9.40
The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer (2007) 8.05
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2006) 6.89
Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant (2009) 6.22
Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood (2002) 5.14
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol (2008) 5.08
Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood (2004) 4.03
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol (2009) 3.89
Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med (2010) 3.84
FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem (2003) 3.41
Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol (2002) 3.20
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood (2008) 3.19
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med (2002) 3.08
Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells (2005) 3.00
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood (2006) 2.94
FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J Cell Biol (2002) 2.86
Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol (2002) 2.84
Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene (2005) 2.80
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood (2010) 2.72
A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem Biol (2006) 2.57
Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res (2009) 2.32
FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta (2011) 2.32
Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells (2006) 2.30
AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood (2005) 2.28
CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1-inducing role of mesenteric lymph node macrophages during colitis. Eur J Immunol (2012) 2.27
The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum Mol Genet (2007) 2.22
Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol Cancer Ther (2008) 2.18
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood (2013) 2.16
SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther (2010) 2.15
Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res (2006) 2.13
Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer (2009) 2.12
Is imatinib still an acceptable first-line treatment for CML in chronic phase? Oncology (Williston Park) (2012) 2.07
An antagonistic pair of FT homologs mediates the control of flowering time in sugar beet. Science (2010) 2.07
Forkhead box proteins: tuning forks for transcriptional harmony. Nat Rev Cancer (2013) 2.02
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood (2012) 2.01
Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol (2008) 1.99
Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression. Mol Cell Biol (2007) 1.96
FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res (2010) 1.95
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood (2005) 1.93
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood (2007) 1.92
The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol (2007) 1.89
Mesenchymal stem cells: the fibroblasts' new clothes? Haematologica (2008) 1.87
Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation (2007) 1.83
Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood (2013) 1.79
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol (2008) 1.76
Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med (2011) 1.75
Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice. Blood (2012) 1.74
In vivo contribution of murine mesenchymal stem cells into multiple cell-types under minimal damage conditions. J Cell Sci (2004) 1.73
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest (2013) 1.72
The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One (2011) 1.71
A model for harmonizing flow cytometry in clinical trials. Nat Immunol (2010) 1.70
The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells. J Biol Chem (2006) 1.68
Left atrial sphericity: a new method to assess atrial remodeling. Impact on the outcome of atrial fibrillation ablation. J Cardiovasc Electrophysiol (2013) 1.67
CD34(-) cells at the apex of the human hematopoietic stem cell hierarchy have distinctive cellular and molecular signatures. Cell Stem Cell (2013) 1.65
Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res (2010) 1.65
β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell (2010) 1.65
Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood (2012) 1.64
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood (2011) 1.63
FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism. Mol Cell Biol (2004) 1.63
HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. Blood (2005) 1.62
Nonhematopoietic/endothelial SSEA-1+ cells define the most primitive progenitors in the adult murine bone marrow mesenchymal compartment. Blood (2006) 1.62
Strontium can increase some osteoblasts without increasing hematopoietic stem cells. Blood (2007) 1.61
Familial amyotrophic lateral sclerosis is associated with a mutation in D-amino acid oxidase. Proc Natl Acad Sci U S A (2010) 1.60
Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung. Stem Cells (2007) 1.59
Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol (2013) 1.58
DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues. Blood (2012) 1.56
Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther (2009) 1.56
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood (2012) 1.54
Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. Leuk Lymphoma (2013) 1.53
Progestins regulate the expression and activity of the forkhead transcription factor FOXO1 in differentiating human endometrium. Mol Endocrinol (2005) 1.51
Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood (2005) 1.51
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica (2009) 1.50
FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol (2009) 1.46
Transcriptional cross talk between the forkhead transcription factor forkhead box O1A and the progesterone receptor coordinates cell cycle regulation and differentiation in human endometrial stromal cells. Mol Endocrinol (2007) 1.45
Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther (2008) 1.44
Engraftment of allogeneic hematopoietic stem cells requires both inhibition of host-versus-graft responses and 'space' for homeostatic expansion. Transplantation (2005) 1.43
The androgen and progesterone receptors regulate distinct gene networks and cellular functions in decidualizing endometrium. Endocrinology (2008) 1.42
A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. Blood (2003) 1.40
FOXO3a induces differentiation of Bcr-Abl-transformed cells through transcriptional down-regulation of Id1. J Biol Chem (2006) 1.40
Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer. PLoS One (2010) 1.40
Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene (2003) 1.39
Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood (2002) 1.39
Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol (2011) 1.38
The immunosuppressive properties of mesenchymal stem cells. Transplantation (2009) 1.38
Differential expression of FOXO1 and FOXO3a confers resistance to oxidative cell death upon endometrial decidualization. Mol Endocrinol (2006) 1.37
Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo. Blood (2010) 1.37